Literature DB >> 16452565

The choice of drugs for schizophrenia.

John M Davis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452565     DOI: 10.1056/NEJMe058298

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  Biol Psychiatry       Date:  2006-10-13       Impact factor: 13.382

Review 2.  Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Authors:  Iris E Sommer; Marieke J H Begemann; Anke Temmerman; Stefan Leucht
Journal:  Schizophr Bull       Date:  2011-03-21       Impact factor: 9.306

Review 3.  Practical issues with amisulpride in the management of patients with schizophrenia.

Authors:  Luca Pani; José M Villagrán; Vassilis P Kontaxakis; Köksal Alptekin
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 4.  Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia.

Authors:  William G Honer; Allen E Thornton; Megan Sherwood; G William MacEwan; Tom S Ehmann; Richard Williams; Lili C Kopala; Ric Procyshyn; Alasdair M Barr
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Understanding and Remediating Social-Cognitive Dysfunctions in Patients with Serious Mental Illness Using Relational Frame Theory.

Authors:  Annemieke L Hendriks; Yvonne Barnes-Holmes; Ciara McEnteggart; Hubert R A De Mey; Gwenny T L Janssen; Jos I M Egger
Journal:  Front Psychol       Date:  2016-02-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.